Relay Therapeutics
RLAY
148 hedge funds and large institutions have $2.02B invested in Relay Therapeutics in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 69 increasing their positions, 23 reducing their positions, and 14 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 23
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
6.53% more ownership
Funds ownership: 104.46% → 110.99% (+6.5%)
6% more funds holding
Funds holding: 140 → 148 (+8)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
40% less capital invested
Capital invested by funds: $3.38B → $2.02B (-$1.36B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$35.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$32.7M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$30.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.9M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$62.3M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$20.5M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$3.12M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$2.99M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.53M |
RLAY Hedge Fund Activity: Q2 2022 in Review
148 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q2 2022, worth a combined $2.02B — down 40% from $3.38B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new RLAY positions and 14 closed out — a net gain of 11 holders — while 69 added to existing stakes and 23 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $35.7M. The largest seller was Fidelity Investments, cutting an estimated $62.3M.
- 148 institutional investors held Relay Therapeutics (RLAY) as of Q2 2022, up from 140 in Q1 2022.
- Funds reported $2.02B of Relay Therapeutics stock for Q2 2022, down 40% quarter-over-quarter.
- 25 funds opened new Relay Therapeutics positions in Q2 2022 and 14 closed out, a net change of +11 holders.
- The largest Relay Therapeutics buyer in Q2 2022 was JP Morgan Chase, an estimated $35.7M added.
- The largest Relay Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $62.3M sold.
Based on aggregated 13F filings for Q2 2022.